Moderna's mRNA-based flu vaccine showed stronger immune response in trials, paving the way for approval. The company plans to resubmit a combination flu and Covid jab for approval, aiming for both shots to be approved next year. The vaccine simplifies vaccination, reducing costs and improving patient uptake.